Search results
Order by most recent / most popular / relevance
Results: 1-10 of 12
Putative class alleges pharma statements about new drug violated securities laws
- Shook Hardy & Bacon LLP
- -
- USA
- -
- May 16 2013
Aveo Pharmaceuticals, Inc. and several of its executives have been targeted in a securities class action filed in a federal court in Massachusetts
PolyMedix expects to raise $25 million for antibiotic development
- Shook Hardy & Bacon LLP
- -
- USA
- -
- March 21 2013
PolyMedix, Inc. stockholders have overwhelmingly approved a reverse stock split of the company's common stock at a ratio of up to fifty-for-one
Cancer genetics IPO raises $6.9 million
- Shook Hardy & Bacon LLP
- -
- USA
- -
- April 18 2013
Rutherford, New Jersey-based Cancer Genetics, Inc., an early-stage diagnostics company that develops genomic-based, oncology tests and services, has
$9.2 million in equity reported to SEC by stem-cell treatment corp.
- Shook Hardy & Bacon LLP
- -
- USA
- -
- August 30 2012
In a regulatory filing with the U.S. Securities and Exchange Commission (SEC), Fate Therapeutics, Inc. has reported that it raised $9.2 million in equity
Biotech companies struggling in public markets
- Shook Hardy & Bacon LLP
- -
- USA
- -
- April 7 2011
While five venture-capital backed biotech companies have reportedly gone public in 2011, each has been forced to lower its offering price even before the initial public offering took place due to weakened demand
IPO proposed by n.c.-based company developing experimental medicines
- Shook Hardy & Bacon LLP
- -
- USA
- -
- August 4 2011
North Carolina-based Argos Therapeutics has filed a Securities and Exchange Commission registration relating to its proposed initial public offering of common stock to raise more than $86 million to help pay for clinical tests of an experimental treatment for kidney cancer
Bio supports new legislation reducing SEC paperwork burdens for small startups
- Shook Hardy & Bacon LLP
- -
- USA
- -
- October 7 2011
A bipartisan bill (S. 1544), introduced in early September 2011, has reportedly gained the support of Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood
IPOs sluggish in 2011 on disappointing returns
- Shook Hardy & Bacon LLP
- -
- USA
- -
- January 19 2012
Biotech initial public offerings (IPOs) tracked the market as a whole in 2011, with fewer filed and returns in the negative column
PROLOR Biotech to raise $75 million for clinical trials on growth hormones
- Shook Hardy & Bacon LLP
- -
- Israel, USA
- -
- April 19 2012
In an April 6, 2012, filing with the U.S. Securities and Exchange Commission, Israel-based PROLOR Biotech, Inc. has registered the sale of common stock on the American Stock Exchange in an amount not to exceed $75 million
Aastrom biosciences announces financing deal to advance CVD treatments
- Shook Hardy & Bacon LLP
- -
- USA
- -
- March 29 2012
Aastrom Biosciences, an Ann Arbor, Michigan-based biotech startup, has announced a $40-million financing deal with large institutional investor Eastern Capital Limited
Current Search
- Workarea - Healthcare
- Workarea - Capital Markets
- Author - Patrick Henderson
Suggested Facets
Author
- Chris A. Johnson (11)
- Debra S. Dunne (1)
- John D. Garretson (9)
- Madeleine McDonough (12)
- Thomas T. Moga (12)